

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director **Patricia Van Arnum**

## **1. Teva, Takeda Form Generics Joint Venture in Japan**

Teva Pharmaceutical Industries Ltd. and Takeda Pharmaceutical Company Limited have agreed to form a generics joint venture in Japan with operations starting in the second quarter of 2016. The move is aligned with a goal of the Japanese government to increase generic drug market penetration in Japan to 80% by the end of fiscal year 2020. [Read More](#)

## **2. Amgen Files for Biosimilar of AbbVie's Humira**

Amgen has submitted a biologics license application with the FDA for a biosimilar to AbbVie's Humira (adalimumab). Humira was AbbVie's top-selling drug in 2014 with sales of approximately \$12.5 billion. [Read More](#)

## **3. Xellia To Acquire Former Ben Venue Manufacturing Facilities from Hikma**

Xellia Pharmaceuticals has acquired the former sterile manufacturing facilities of Ben Venue Laboratories in Bedford, Ohio from a wholly owned subsidiary of Hikma Pharmaceuticals. Xellia plans to begin commercial production at the site within 24 months following investment, including the training of a new organization to operate the plant. [Read More](#)

## **4. Novo Nordisk Sets Target of 100% Renewable Energy for Electricity for Global Production**

Novo Nordisk plans to use electricity from renewable sources at all its global production sites by 2020. Already today, the company's production sites in Denmark, Brazil, and Japan use electricity from renewable sources, and it recently signed an agreement to use wind power for its production site in Tianjin, China. [Read More](#)

## **5. Teva, Heptares Sign \$400 Million Small-Molecule Drug Pact**

Teva Pharmaceutical Industries and Heptares Therapeutics have formed a licensing and drug-discovery agreement under which Teva will receive exclusive global rights to develop, manufacture, and commercialize small-molecule calcitonin gene-related peptide antagonists discovered by Heptares for treating migraines in a deal valued up to \$410 million. [Read More](#)

## **6. EC OKs Novartis' Chronic Heart Failure Drug**

The European Commission has approved Novartis' Entresto (sacubitril/valsartan) for treating chronic heart failure. The drug was approved by the FDA earlier this year. Novartis estimates possible peak sales in excess of \$5 billion on a global basis. [Read More](#)

## **7. FDA OKs Lilly's Lung Cancer Drug**

The FDA has approved Eli Lilly and Company's Portrazza (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with metastatic squamous non-small cell lung cancer. [Read More](#)

## 8. [President Obama Signs Law to Expedite Controlled Substances Scheduling](#)

President Barack Obama has signed a new law that seeks to address concerns over delays by the Drug Enforcement Administration in scheduling (i.e., classifying) a controlled substance following FDA approval. [Read More](#)

## 9. [Merck KGaA Plans Investment in Africa](#)

Merck KGaA said it plans to considerably expand its presence on the African continent over the next five years in both its pharmaceuticals and life sciences businesses, which includes doubling its workforce and sales on the continent by 2020. [Read More](#)

## 10. [Sanofi, AstraZeneca Exchange 210,000 Small Molecules in Open Innovation Model](#)

Sanofi and AstraZeneca have announced a direct exchange of 210,000 compounds from their respective, proprietary compound libraries under an open innovation collaboration model between the two companies. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
Have an enjoyable weekend!*

---

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

[Forward this email](#)



This email was sent to [esanders@dcat.org](mailto:esanders@dcat.org) by [dcatnews@dcat.org](mailto:dcatnews@dcat.org) | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)

Drug, Chemical, & Associated Technologies Association | One Union Street | Suite 208 | Robbinsville | NJ | 08691